Home » Healthcare » Pharmaceuticals » Biosimilars Treatment Market

Biosimilars Treatment Market By Product (Recombinant Non – Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Application (Oncology, Chronic And Autoimmune Disease, Blood Disorders, Growth Hormone Disease, Infectious Disease) – Growth, Future Prospects And Competitive Analysis 2017 – 2025

Price: $4999

Published: | Report ID: 1687 | Report Format : PDF

This report on the global biosimilars market studies the increasing demand for biosimilars as the number of biologic drugs used to treat chronic diseases is set to expire in the next 3-5 years, growing pressure to curtail healthcare expenditure, the cost-effectiveness of biosimilars, and strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars.

For the purpose of this study, the biosimilars market is segmented into a product (recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides) and application type (oncology, chronic and autoimmune disorders, blood disorders, growth hormone disease, and infectious disease); market size estimates and forecasts for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for the biosimilars market comprises projected market sales of Phase III drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (SB4, HX575, ABP 980, and M834), sponsor, depicted peak sales by leading market experts, and other factors.

The geographic segmentation of the global biosimilars market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

Based on product types, the global biosimilars market is categorized into:

  • Recombinant non-glycosylated proteins (insulin, filgrastim, somatropin)
  • Recombinant glycosylated proteins (monoclonal antibodies, erythropoietin)
  • Recombinant peptides (glucagon, calcitonin)

According to market experts, recombinant non-glycosylated proteins are expected to dominate the product segment due to the growing incidence of diabetes, the presence of several versions of insulin in the market, and the launch of cost-effective products.

The recombinant glycosylated proteins will record the fastest growth in the biosimilar product segment as the need for erythropoietin to counter blood-related disorders is increasing due to high-priced biologics and frequent application. Overall, the global biosimilars market is highly competitive, with multiple players like Pfizer, Inc., Biocon, F. Hoffman-La Roche AG, Amgen, Inc., etc., specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the technological advancement in the biosimilars market.

Based on application, the global biosimilars market is categorized into:

  • Oncology
  • Chronic and autoimmune diseases
  • Blood disorder
  • Growth hormone
  • Infectious disease

Oncology is expected to dominate the application segment due to rising incidences of cancer, the high cost of biologics, and the pressure to reduce healthcare expenditure. In the base year 2016, biosimilar applications for autoimmune disease and chronic disease showed great potential due to the changing off-patent scenario. Blood disease biosimilars are expected to grow significantly between 2017 and 2025, owing to the high cost of reference biologics and their widespread use.

The key factors assisting the biosimilar market’s growth are the increasing prevalence of chronic disease, the aging population, the cost-effectiveness of biosimilars, and government initiatives to promote biosimilars, for example. The European Medicines Agency (EMA) has finalized the guidelines on biosimilars with their elements described in ICH (Q5E).

For the purpose of this study, the global biosimilars market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

In 2016, North America was identified as the largest market for biosimilars. According to the Centers for Disease Control and Prevention, in 2012, about half of adults, i.e., 117 million people, suffered from chronic disease, which can be considered a potential market for biosimilars.

According to the World Health Organization, over one-third of the European population above the age of 15 suffers from chronic disease. Europe is expected to be the second-largest market due to rising public awareness of the chronic disease and improved healthcare infrastructure. Newly approved biosimilar molecules have a good acceptance and penetration rate in the European market.

The growth of the Asia Pacific biosimilar market is attributed to factors like the rising prevalence of chronic diseases, increasing investments in R&D, and higher disposable income in these regions. However, factors such as the high prevalence of chronic disease, developing healthcare infrastructure, increasing awareness among people about healthcare, and an aging population are going to fuel the rapid growth of the biosimilars market in Latin America, the Middle East, and Africa in the near future.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Biosimilars Market Portraiture
2.2 Global Biosimilars Market, by Product, 2016 (US$ Mn)
2.3 Global Biosimilars Market, by Application 2016 (US$ Mn)
2.4 Global Biosimilars Market, by Geography, 2016 (Value %)

Chapter 3 Global Biosimilars Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of cancer and chronic disease and geriatric population
3.2.2 Patent expiry of biologics and government initiatives to promote biosimilars
3.3 Market Restraints
3.3.1 High complexities involved in the manufacturing of biosimilars
3.3.2 Rigorous regulatory frame work governing their approval in countries around the world
3.4 Market Opportunities
3.4.1 Cost effectiveness of biosimilars in comparison to costly biological drugs.
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Biosimilars , by Key Players

Chapter 4 Global Biosimilar Market, By Type of Product
4.1 Introduction
4.2 Recombinant non – glycosylated proteins
4.3 Recombinant glycosylated proteins
4.4 Recombinant peptides

Chapter 5 Global Biosimilar Market, By Application
5.1 Market Analysis
5.2 Oncology
5.3 Chronic and autoimmune disease
5.4 Blood disorders
5.5 Growth hormone disease
5.6 Infectious disease

Chapter 6 Global Biosimilar Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Pfizer, Inc.
7.2 Sandoz International GmbH
7.3 Teva Pharmaceutical Industries Limited
7.4 Amgen Inc.
7.5 Biocon
7.6 Dr. Reddy’s Laboratories
7.7 F. Hoffman – La Roche Ltd.
7.8 Celltrion, Inc.
7.9 Samsung Bioepis
7.10 Eli Lily, Inc.

List of Figures

FIG. 1 Biosimilars Market: Research Methodology
FIG. 2 Global Biosimilars Market, by Product 2016 (US$ Mn)
FIG. 3 Global Biosimilars Market, by Application, 2016 (US$ Mn)
FIG. 4 Global Biosimilars Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography,2016
FIG. 6 Market Positioning of Key Biosimilars Vendors, 2016
FIG. 7 Recombinant non – glycosylated proteins Product Market, 2015 – 2025 (US$ Mn)
FIG. 8 Recombinant glycosylated proteins Product Market, 2015 – 2025 (US$ Mn)
FIG. 9 Recombinant peptides Product Market, 2015 – 2025 (US$ Mn)
FIG. 10 Oncology Application Market, 2015 – 2025 (US$ Mn)
FIG. 11 Chronic and autoimmune disease Appication Market, 2015 – 2025 (US$ Mn)
FIG. 12 Blood disorders Application Market, 2015 – 2025 (US$ Mn)
FIG. 13 Growth hormone disease Application Market, 2015 – 2025 (US$ Mn)
FIG. 14 Infectious disease Application Market, 2015 – 2025 (US$ Mn)
FIG. 15 North America Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 16 Europe Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 17 Asia-Pacific Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 18 Latin America Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 19 Middle East and Africa Biosimilars Market , 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Biosimilars Market, By Product, 2015-2025 (US$ Mn)
TABLE 2 Global Biosimilars Market, By Application, 2015-2025 (US$ Mn)
TABLE 3 Global Biosimilars Market, By Geography, 2015 – 2025 (US$ Mn)
TABLE 4 Pfizer, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 5 Sandoz International GmbH : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 6 Teva pharmaceutical Industries Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 7 Amgen Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 8 Biocon: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 9 Dr. Reddy’s Laboratories : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 10 F. Hoffman – La Roche Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 11 Celltrion, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 12 Samsung Bioepis : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Eli Lily, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)

Frequently Asked Question

What is the size of Biosimilars Treatment Market?

The market for Biosimilars Treatment Market is expected to reach USD$ 25.83 Bn in 2025.

What is the Biosimilars Treatment Market CAGR?

The Biosimilars Treatment Market is expected to see significant CAGR growth over the coming years, at 23.1%.

What is the Forecast period considered for Biosimilars Treatment Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Biosimilars Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

Pfizer, Inc., Biocon, F. Hoffman-La Roche AG, Amgen, Inc., etcme of the major players in the global market.

Animal Drug Compounding Market

Published:
Report ID: 40870

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Anti-Cancer Drugs Market

Published:
Report ID: 39971

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Congenital Disabilities Market

Published:
Report ID: 39845

Acquired Hemophilia Treatment Market

Published:
Report ID: 1124

Tyrosine Kinase Inhibitors (TKIs) Market

Published:
Report ID: 39696

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN